Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the investigators can measure inhibition of a protein,
Src (named for Sarcoma), in tissue and blood in patients with a diagnosis of endometrial
cancer. Dasatinib is a drug that blocks the activity of an important protein in cancer cells
called Src. The investigators can measure the blocking of Src in the bloodstream. However,
the investigators do not know if measures in the bloodstream reflect blockage of Src in
cancer tissue. The investigators are doing this study to try and see if the investigators can
match what the investigators see in cancer tissue to what the investigators see in the
bloodstream. the investigators hope that in the future, the investigators can use blood to
measure protein inhibition by dasatinib instead of asking patients to undergo repeat
biopsies.